|19/08/21||TGEM031||Delivery of anticancer drugs to cancer cells
||TGEM031 is a modified β-Cyclodextrin and increased in vitro antitumor activities of doxorubicin (DOX), vinblastine and paclitaxel. The complex of DOX with TGEM031 markedly increased antitumor activity of DOX, after intravenous administration to tumor-bearing mice.||問合せ|
|19/07/31||TGEM030||Innovative technology enabling improved GI absorption of the insoluble drug
||A patented technology based on lipidic compositions which form optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. TGEM030 enables development of superior oral products with: Improved solubilization and high drug loading capacity, improved bioavailability, faster and more consistent absorption leading to reduced variability and reduced sensitivity to food effects. TGEM030 utilizes bioacceptable excipients and conventional manufacturing processes.
|19/07/08||TGEM029||Sustained release PLGA
||Poly lactide-co-glycolide acid (PLGA) microsphere technology for sustained release of drugs. Versatile drug release profiles could be achieved by adjusting the formulation compositions and effective plasma drug concentration could be maintained for several weeks or months upon one injection. In addition, the pharmacokinetic and pharmacodynamics evaluation models for sustained release technology have been established which could speed up product development.||問合せ|
|19/07/08||TGEM028||Posterior eye delivery
||An ocular delivery technology specially designed to topically deliver hydrophobic small molecular across ocular tissues into posterior ocular tissues.
The eye drop based delivery technology can overcome the delivery obstacle of tissue barriers to transport therapeutics to posterior ocular target tissue. This breakthrough technology is expected to bring broader applications for posterior ocular drug delivery
|19/07/08||TGEM027||Site-specific linker toxin
||The disadvantages of traditional conjugation technologies include the lack of specificity at the connecting positions of the antibodies and the variable number of connections. The new technology can overcome these disadvantages by improving homogeneity of ADC via site-specific conjugation. The site-specific linker-toxin shows better homogeneity, stability and efficacy.||問合せ|
||This technology enables peptide and oligonucleotide drugs to be delivered efficiently into cells through conjugating a cell-penetrating motif (CPM) onto drug candidate. Unlike liposomal or other nanoparticle formulation, the CPM technology requires no encapsulation process and provides formulated drug product with high stability and storage condition tolerances.||問合せ|
|19/06/06||TGEM025||Innovative proteoliposome methodology for rapid discovery of biomarkers, ligands and/or receptors
||A newly developed one-step direct transfer technology for MALDI-mass spectrometry (MS) can eliminate time-consuming intermediate processes and separate or remove plasma high abundant proteins, and therefore is useful for rapid and efficientt peptide profiling of biological samples. In addition, this technology can be used for rapid identification of ligands and cell surface receptors including GPCRs and GPI anchors by combining with a library of membrane proteins keeping binding capability reconsitututed on artificial phopholipid bilayers of liposomes.||問合せ|
|19/05/30||TGEM024||Novel lymphatic delivery system
||A novel hyaluronic acid-based nanocarriers that could deliver more drug to lymph nodes.
This delivery system may offer significant advantages for the use of platinum medicines in the management of locally advanced cancers.
Organic solvent-free nanocarriers process.
Active targeting to lymph node and tumor.
|19/05/30||TGEM023||Innovative formulation for insoluble drugs
||Novel platform of formulation design and evaluation include concept of formulation design, composition of formulation, in vitro dissolution study, and in vivo absorption test. This new concept of formulation design utilizes solubility buster with traditional excipient to resolve solubility problem of drugs. This platform could be widely applied to BCS II drugs and shorten development process. Traditional excipient and solubility buster are commercial products that are easy to purchase without limitation.||問合せ|
|19/04/02||TGEM022||Innovative nanoparticle formulation
||Achieved higher content of drug, more homogeneous particle size distribution, lower cost (1/10) and easier mass production compared to conventional methods.
Easy to control particle size (2 nm ~ 500 nm).
Provide DDS function to the drug and stay the drug in the cell for a long time.
Enable re-development of compounds that abandon development with side effects and insufficient effect.
The substrate used in the nanoparticle formulation are used in approved medicines (FDA).